Today, we’re offering insight into the latest numbers from Biogen, AstraZeneca and GSK. The $381 million Biogen got from royalties tied to Roche’s multiple sclerosis drug Ocrevus were about $21 million above analyst forecasts. Etcamah, a breast cancer drug important to AstraZeneca’s future, has been delayed in the U.S. Dealmaking has helped the British pharma acquire cancer drugs like Jemperli, Zejula and Blenrep. In an earnings presentation Tuesday, though, the company spotlighted its next wave of oncology drugs as critical revenue drivers in the years ahead.